AnaptysBio, Inc. (ANAB)

Market Cap	1.82B +247.6%
Revenue (ttm)	234.60M +157.0%
Net Income	-13.23M
EPS	-0.46
Shares Out	28.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	270,210
Open	64.68
Previous Close	64.67
Day's Range	61.54 - 65.00
52-Week Range	15.32 - 66.66
Beta	0.41
Analysts	Strong Buy
Price Target	70.60 (+11.64%)
Earnings Date	Mar 3, 2026

About ANAB

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 26, 2017
• Employees: 104
• Stock Exchange: NASDAQ
• Ticker Symbol: ANAB
• Website: https://www.anaptysbio.com

Financial Performance

In 2025, AnaptysBio's revenue was $234.60 million, an increase of 157.01% compared to the previous year's $91.28 million. Losses were -$13.23 million, -90.89% less than in 2024.

Analyst Summary

According to 10 analysts, the average rating for ANAB stock is "Strong Buy." The 12-month stock price target is $70.6, which is an increase of 11.64% from the latest price.

Price Target

$70.6

(11.64% upside)

Analyst Consensus: Strong Buy